title: The histone H2B-specific ubiquitin ligase RNF20/hBRE1 acts as a putative tumor suppressor through selective regulation of gene expression.
abstract: Histone monoubiquitylation is implicated in critical regulatory processes. We explored the roles of histone H2B ubiquitylation in human cells by reducing the expression of hBRE1/RNF20, the major H2B-specific E3 ubiquitin ligase. While H2B ubiquitylation is broadly associated with transcribed genes, only a subset of genes was transcriptionally affected by RNF20 depletion and abrogation of H2B ubiquitylation. Gene expression dependent on RNF20 includes histones H2A and H2B and the p53 tumor suppressor. In contrast, RNF20 suppresses the expression of several proto-oncogenes, which reside preferentially in closed chromatin and are modestly transcribed despite bearing marks usually associated with high transcription rates. Remarkably, RNF20 depletion augmented the transcriptional effects of epidermal growth factor (EGF), increased cell migration, and elicited transformation and tumorigenesis. Furthermore, frequent RNF20 promoter hypermethylation was observed in tumors. RNF20 may thus be a putative tumor suppressor, acting through selective regulation of a distinct subset of genes.
authors.affiliation: Department of Molecular Cell Biology, The Weizmann Institute of Science, Rehovot 76100, Israel.
authors.forename: Efrat
authors.initials: E
authors.lastname: Shema
authors.forename: Itay
authors.initials: I
authors.lastname: Tirosh
authors.forename: Yael
authors.initials: Y
authors.lastname: Aylon
authors.forename: Jing
authors.initials: J
authors.lastname: Huang
authors.forename: Chaoyang
authors.initials: C
authors.lastname: Ye
authors.forename: Neta
authors.initials: N
authors.lastname: Moskovits
authors.forename: Nina
authors.initials: N
authors.lastname: Raver-Shapira
authors.forename: Neri
authors.initials: N
authors.lastname: Minsky
authors.forename: Judith
authors.initials: J
authors.lastname: Pirngruber
authors.forename: Gabi
authors.initials: G
authors.lastname: Tarcic
authors.forename: Pavla
authors.initials: P
authors.lastname: Hublarova
authors.forename: Lilach
authors.initials: L
authors.lastname: Moyal
authors.forename: Mali
authors.initials: M
authors.lastname: Gana-Weisz
authors.forename: Yosef
authors.initials: Y
authors.lastname: Shiloh
authors.forename: Yossef
authors.initials: Y
authors.lastname: Yarden
authors.forename: Steven A
authors.initials: SA
authors.lastname: Johnsen
authors.forename: Borivoj
authors.initials: B
authors.lastname: Vojtesek
authors.forename: Shelley L
authors.initials: SL
authors.lastname: Berger
authors.forename: Moshe
authors.initials: M
authors.lastname: Oren
mesh_terms: D000818:Animals; D001943:Breast Neoplasms / Q000235:genetics / Q000378:metabolism; D002465:Cell Movement; D002471:Cell Transformation, Neoplastic; D002843:Chromatin / Q000235:genetics / Q000378:metabolism; D019175:DNA Methylation; D004273:DNA, Neoplasm / Q000737:chemistry / Q000235:genetics / Q000378:metabolism; D004815:Epidermal Growth Factor / Q000494:pharmacology; D005260:Female; D005786:Gene Expression Regulation / Q000187:drug effects; D006367:HeLa Cells; D006657:Histones / Q000737:chemistry / Q000378:metabolism*; D006801:Humans; D051379:Mice; D008819:Mice, Nude; D011401:Promoter Regions, Genetic; D012319:RNA Polymerase II / Q000378:metabolism; D034741:RNA, Small Interfering / Q000235:genetics; D013489:Suppression, Genetic; D016159:Tumor Suppressor Protein p53 / Q000235:genetics / Q000378:metabolism; D025521:Tumor Suppressor Proteins / Q000235:genetics / Q000378:metabolism*; D044767:Ubiquitin-Protein Ligases / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism*; D054875:Ubiquitination
chemical_list: D002843:Chromatin; D004273:DNA, Neoplasm; D006657:Histones; D034741:RNA, Small Interfering; C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53; D025521:Tumor Suppressor Proteins; D004815:Epidermal Growth Factor; C506646:RNF20 protein, human; C571257:RNF20 protein, mouse; D044767:Ubiquitin-Protein Ligases; D012319:RNA Polymerase II